deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02141490

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney) Cancers

Sponsor: National Cancer Institute (NCI)

Conditions Bladder Cancer Kidney Cancer Prostate Cancer
Interventions Ferumoxytol Magnetic Resonance Imaging (MRI)
Updated 17 times since 2017 Last updated: Sep 5, 2019 Started: May 15, 2014 Primary completion: Nov 20, 2018 Completion: Nov 20, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bladder Cancer and Kidney Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 17 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE2

  5. Sep 2019 — Oct 2019 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. May 2019 — Sep 2019 [monthly]

    Completed PHASE2

  2. Feb 2019 — May 2019 [monthly]

    Completed PHASE2

  3. Jan 2019 — Feb 2019 [monthly]

    Completed PHASE2

  4. Dec 2018 — Jan 2019 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  6. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  7. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  8. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations